Dr. Martens (LSE:DOCS) has re-presented its historical figures under a new two-segment structure, in a notice filed on 7 October 2026, giving investors a fresh baseline before its next results. The shares closed at 64.90p on 2 November, with no results published today.

What happened

Dr. Martens (LSE:DOCS) is a constituent of the FTSE All-Share index in the consumer products and services sector. Its most recent filing was a total voting rights notice on 30 October, a routine item. The most substantive recent announcement is the "Group Reporting Changes" notice of 7 October.

According to an AI-generated summary from available data, the group now reports two market-based segments, "US" and "Global Markets (ex US)", with effect from 1 April 2026. The change alters how results are allocated between segments. Consolidated revenue, gross margin, profit before tax, financial position and Earnings Per Share are all unchanged.

The re-presented data put FY26 Revenue at £764.9m, against £787.6m in FY25. US revenue was £258.6m, compared with £270.3m. Global Markets (ex US) contributed £506.3m, compared with £517.3m.

The company will also report Demand generating spend at group level, at £56.3m in FY26 and £56.5m in FY25. Separately, mules move from the sandals category to shoes, which affects the FY26 revenue mix by about 4%.

Why it matters for investors

On our arithmetic, group revenue fell about 2.9% between the two years. The US fell about 4.3% and the rest of the world about 2.1%. The US represented 33.8% of FY26 revenue, slightly below its 34.3% share a year earlier.

In our view, the practical effect is that the US now has its own line, so progress in that market can be tracked directly in future reports. The new baseline does not itself change the group's earnings, and the summary does not suggest otherwise. Marketing spend was broadly flat in cash terms while revenue fell, taking it from about 7.2% to about 7.4% of revenue by our calculation.

Other recent items are less easy to read. Director or senior manager shareholding notices were filed on 16 September and on 8, 14 and 16 October, but we did not review their contents, so no signal is drawn from them. On 24 September, the company also issued a non-regulatory notice about a new Brand platform called "With Bouncing Soles". Admission to trading notices appeared on 1 and 30 September, and we did not review those either.

How the shares have performed

A market data page dated 2 November showed a close of 64.90p, down 1.00p or 1.52% on the day, after a range of 61.60p to 68.90p. The 52-week range ran from 59.35p, on 30 March 2026, to 93.30p, on 6 November 2025.

That left the shares about 30% below the high and 9% above the low, by our calculation. The same page listed a Dividend Yield of 2.63% and a Market Value of £628.3m as at that date.

What to watch next

Half-year results will be the first set of numbers under the new structure, on our reading of the 1 April start date. We could not confirm their publication date from the material retrieved, so readers should check the company's financial calendar.

The points to test will be whether US revenue stabilises against the £258.6m full-year base and whether marketing spend stays near the FY26 level.